Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial

Bipin B Bhakta, J Alastair Cozens, M Anne Chamberlain, John M Bamford

Abstract

Objectives—After stroke, abnormal arm posture due to spasticity in a functionally useless arm may interfere with self care tasks. In these patients botulinum toxin treatment presents an opportunity to reduce disability. The purpose was to investigate whether reduction in spasticity after botulinum toxin treatment translates into reduction in disability and carer burden.

Methods—Forty patients with stroke with spasticity in a functionally useless arm (median duration 3.1 years) were randomised to receive intramuscular botulinum toxin type A (BT-A; Dysport) (n=20) or placebo (n=20) in a total dose of 1000 MU divided between elbow, wrist, and finger flexors. Spasticity (using the modified Ashworth scale), muscle power, joint movement, and pain were assessed. Disability and carer burden were measured using aneight item and a four item scale respectively. Two baseline and three post-treatment assessments (weeks 2, 6, and 12) were made. Concurrent treatments as far as possible remained unchanged and not optimised.

Results—Disability improved at week 6 with BT-A compared with placebo. This effect, present at week 2, wore off by week 12. Reduction in carer burden was seen at week 6 with BT-A and continued for at least 12 weeks. Forearm flexor spasticity was reduced with BT-A up to 12 weeks after treatment. Although significant improvement in elbow flexor spasticity was seen at week 2 with BT-A compared with placebo, this effect was not evident at weeks 6 and 12. Arm pain was not improved after BT-A. Grip strength was reduced with BT-A. No serious BT-A related adverse effects were reported.

Conclusion—BT-A is useful for treating patients with stroke who have self care difficulties due to arm spasticity. The decision to treat should also include relief of carer burden. As muscle weakness may occur, its potential impact on functional activities must be assessed before intervention.

Keywords: stroke; spasticity; botulinum toxin

Stroke is a major cause of death and morbidity with an overall age and sex adjusted incidence for first stroke of 2.0/1000/year.1 Arm involvement is common with up to 69% having weakness on admission to hospital.2 Long term recovery of arm movement is often poor in patients presenting with a completely paralysed arm with recovery depending on the extent of improvement in the first 6 to 9 weeks.3 In patients with a functionally useless arm, abnormal posture due to spasticity may interfere with self care tasks.4 In these patients botulinum toxin treatment presents an opportunity to reduce disability.

Botulinum neurotoxin reduces spasticity by blocking acetylcholine release at the neuromuscular junction.5 Seven neurotoxin serotypes have been identified, of which botulinum toxin type A (BT-A) is currently used in clinical practice. Botulinum toxin type A offers the possibility of a targeted treatment for “focal” spasticity in the context of managing specific disabilities. It has advantages over systemic treatments which may weaken unaffected muscles and, compared with local treatments such as phenol nerve blocks, sensation is not affected.6 Although open6–10 and randomised control trials11 12 have shown that BT-A reduces arm spasticity after stroke, its impact on disability and carer burden has been difficult to quantify. Simpson et al13 suggest that future research should explore potential functional gains. To consider this issue, the primary aim of this study was to investigate the impact of BT-A on disability and carer burden in people with arm spasticity after stroke.

Method

Patients

Fifty four consecutive patients with stroke with chronic hemiparesis referred to the rehabilitation medicine unit for consideration of botulinum toxin for arm spasticity were initially assessed. Twelve patients had functionally useful movement in the paretic arm and were therefore excluded. Two patients declined to participate. The remaining 40 patients, who had finger flexor or elbow flexor spasticity>2 on the modified Ashworth score (MAS)13 and at least moderate difficulty with two out of eight items defining patient disability (described later), were recruited. Patients had not previously received BT-A or phenol nerve block for spasticity and were at least 6 months post-stroke. Approval was obtained from the local...
Table 1  Clinical characteristics and trial drug dosage

<table>
<thead>
<tr>
<th></th>
<th>Botulinum toxin group (n=20)</th>
<th>Placebo group (n=20)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Female sex</strong></td>
<td>7 (35%)</td>
<td>10 (50%)</td>
</tr>
<tr>
<td><strong>Age at stroke</strong></td>
<td>60.2 (22.6–77.6)</td>
<td>53.8 (11.2–72.8)</td>
</tr>
<tr>
<td><strong>Time to recruitment (y)</strong></td>
<td>3.1 (0.8–33.2)</td>
<td>2.7 (0.5–15.0)</td>
</tr>
<tr>
<td><strong>Type of stroke - infarct</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Haemorrhage</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Right handed</strong></td>
<td>18 (90%)</td>
<td>20 (100%)</td>
</tr>
<tr>
<td><strong>Muscles injected:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Barthel index</strong></td>
<td>13.5 (4–20)</td>
<td>13.5 (5–20)</td>
</tr>
<tr>
<td><strong>Right hemiparesis</strong></td>
<td>8 (40%)</td>
<td>6 (30%)</td>
</tr>
<tr>
<td><strong>Female sex</strong></td>
<td>7 (35%)</td>
<td>10 (50%)</td>
</tr>
<tr>
<td><strong>Age at stroke</strong></td>
<td>60.2 (22.6–77.6)</td>
<td>53.8 (11.2–72.8)</td>
</tr>
<tr>
<td><strong>Time to recruitment (y)</strong></td>
<td>3.1 (0.8–33.2)</td>
<td>2.7 (0.5–15.0)</td>
</tr>
<tr>
<td><strong>Type of stroke - infarct</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Haemorrhage</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Right handed</strong></td>
<td>18 (90%)</td>
<td>20 (100%)</td>
</tr>
<tr>
<td><strong>Muscles injected:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Barthel index</strong></td>
<td>13.5 (4–20)</td>
<td>13.5 (5–20)</td>
</tr>
</tbody>
</table>

*Median (range).

OUTCOME MEASURES

As global measures (for example, the Barthel index) fail to identify benefits reported by patients, disability and carer burden scales developed to measure the impact of upper limb spasticity were used as primary outcomes. The disability scale consisted of eight items (cleaning the palm, cutting fingernails, putting the paretic arm through sleeves, cleaning under the armpit, cleaning around the elbow, standing balance, walking balance, ability to perform a home upper limb physiotherapy exercise programme) and the carer burden scale consisted of four items (cleaning the palm, cutting the fingernails, dressing, cleaning under the armpit). Each item was rated by the patient or carer on a five point Likert scale (“no difficulty” to “cannot do task”) at its most difficult over the preceding week. Item scores were summed and divided by the number of items answered giving a summary disability score (0=no disability, 4=maximum disability) and carer burden score (0=no carer burden, 4=maximum carer burden). The patient completed the rating of disability and the carer completed the carer burden scale. Secondary outcome measures were: (1) Medical Research Council (MRC) muscle power grading of shoulder abductors, elbow flexors, and extensors and wrist dorsi/palmar flexors; (2) maximum voluntary grip strength (MVG) (Newtons) using hand dynamometry; (3) spasticity in the shoulder adductors, elbow flexor, and finger flexor muscles using the MAS; (4) protractor goniometry for shoulder, elbow, and wrist range of movement (ROM); (5) self completed 0–10 rating of pain with the limits set by the statements “no pain” and worst pain possible and scoring based on the worst pain present during the previous week. A separate score for pain in the shoulder, upper arm, elbow, forearm, wrist, and hand was obtained and summed to obtain a total pain score between 0 and 60.

STUDY DESIGN

We performed a single centre, randomised, double blind, parallel trial. Patients received either 1000 mouse units (MU) of BT-A (Dysport) or equivalent placebo (supplied by Ipsen Ltd) diluted in 10 ml 0.9% saline. In an attempt to emulate clinical practice some flexibility was allowed between patients in the dose of trial drug given to individual muscles. Dose selection for individual muscles was based on clinical judgement of spasticity as measured by the MAS by a single investigator (BBB). Trial drug was administered by a single investigator (BBB). Ordering, labelling, blinding, recording, and dispensing of trial drug vials were tasks independently undertaken by the pharmacy according to an individual randomisation code produced by the University medical statistics department. Placebo and BT-A were identical in appearance and not accompanied by symptoms at injection that would allow them to be distinguished by patient or researcher. Two baseline assessments were made 1 week apart (weeks –1 and 0) before injection of trial drug at week 0 into spastic muscles (table 1) using anatomical landmarks. Assessments were made at 2, 6, and 12 weeks post-treatment with patients and investigator not permitted to see the responses at previous assessments. The patients completed the disability rating scale and pain score and the carer completed the carer burden scale. All other clinical measurements were performed by a single investigator (BBB). As far as possible existing medical and physical antispasticity treatments were unaltered. One patient died of myocardial infarction after randomisation and therefore no post-treatment measurements were possible (placebo group). One patient was unable to attend the week 2 assessment (placebo group), one patient the week 2 and week 6 assessment (placebo group), and two patients declined the week 12 assessment (BT-A group). The trial was unmasked once all patient assessments had been completed.

STUDY DESIGN

We performed a single centre, randomised, double blind, parallel trial. Patients received either 1000 mouse units (MU) of BT-A (Dysport) or equivalent placebo (supplied by Ipsen Ltd) diluted in 10 ml 0.9% saline. In an attempt to emulate clinical practice some flexibility was allowed between patients in the dose of trial drug given to individual muscles. Dose selection for individual muscles was based on clinical judgement of spasticity as measured by the MAS by a single investigator (BBB). Trial drug was administered by a single investigator (BBB). Ordering, labelling, blinding, recording, and dispensing of trial drug vials were tasks independently undertaken by the pharmacy according to an individual randomisation code produced by the University medical statistics department. Placebo and BT-A were identical in appearance and not accompanied by symptoms at injection that would allow them to be distinguished by patient or researcher. Two baseline assessments were made 1 week apart (weeks –1 and 0) before injection of trial drug at week 0 into spastic muscles (table 1) using anatomical landmarks.

Assessments were made at 2, 6, and 12 weeks post-treatment with patients and investigator not permitted to see the responses at previous assessments. The patients completed the disability rating scale and pain score and the carer completed the carer burden scale. All other clinical measurements were performed by a single investigator (BBB). As far as possible existing medical and physical antispasticity treatments were unaltered. One patient died of myocardial infarction after randomisation and therefore no post-treatment measurements were possible (placebo group). One patient was unable to attend the week 2 assessment (placebo group), one patient the week 2 and week 6 assessment (placebo group), and two patients declined the week 12 assessment (BT-A group). The trial was unmasked once all patient assessments had been completed.

STUDY DESIGN

We performed a single centre, randomised, double blind, parallel trial. Patients received either 1000 mouse units (MU) of BT-A (Dysport) or equivalent placebo (supplied by Ipsen Ltd) diluted in 10 ml 0.9% saline. In an attempt to emulate clinical practice some flexibility was allowed between patients in the dose of trial drug given to individual muscles. Dose selection for individual muscles was based on clinical judgement of spasticity as measured by the MAS by a single investigator (BBB). Trial drug was administered by a single investigator (BBB). Ordering, labelling, blinding, recording, and dispensing of trial drug vials were tasks independently undertaken by the pharmacy according to an individual randomisation code produced by the University medical statistics department. Placebo and BT-A were identical in appearance and not accompanied by symptoms at injection that would allow them to be distinguished by patient or researcher. Two baseline assessments were made 1 week apart (weeks –1 and 0) before injection of trial drug at week 0 into spastic muscles (table 1) using anatomical landmarks.

Assessments were made at 2, 6, and 12 weeks post-treatment with patients and investigator not permitted to see the responses at previous assessments. The patients completed the disability rating scale and pain score and the carer completed the carer burden scale. All other clinical measurements were performed by a single investigator (BBB). As far as possible existing medical and physical antispasticity treatments were unaltered. One patient died of myocardial infarction after randomisation and therefore no post-treatment measurements were possible (placebo group). One patient was unable to attend the week 2 assessment (placebo group), one patient the week 2 and week 6 assessment (placebo group), and two patients declined the week 12 assessment (BT-A group). The trial was unmasked once all patient assessments had been completed.

STUDY DESIGN

We performed a single centre, randomised, double blind, parallel trial. Patients received either 1000 mouse units (MU) of BT-A (Dysport) or equivalent placebo (supplied by Ipsen Ltd) diluted in 10 ml 0.9% saline. In an attempt to emulate clinical practice some flexibility was allowed between patients in the dose of trial drug given to individual muscles. Dose selection for individual muscles was based on clinical judgement of spasticity as measured by the MAS by a single investigator (BBB). Trial drug was administered by a single investigator (BBB). Ordering, labelling, blinding, recording, and dispensing of trial drug vials were tasks independently undertaken by the pharmacy according to an individual randomisation code produced by the University medical statistics department. Placebo and BT-A were identical in appearance and not accompanied by symptoms at injection that would allow them to be distinguished by patient or researcher. Two baseline assessments were made 1 week apart (weeks –1 and 0) before injection of trial drug at week 0 into spastic muscles (table 1) using anatomical landmarks.

Assessments were made at 2, 6, and 12 weeks post-treatment with patients and investigator not permitted to see the responses at previous assessments. The patients completed the disability rating scale and pain score and the carer completed the carer burden scale. All other clinical measurements were performed by a single investigator (BBB). As far as possible existing medical and physical antispasticity treatments were unaltered. One patient died of myocardial infarction after randomisation and therefore no post-treatment measurements were possible (placebo group). One patient was unable to attend the week 2 assessment (placebo group), one patient the week 2 and week 6 assessment (placebo group), and two patients declined the week 12 assessment (BT-A group). The trial was unmasked once all patient assessments had been completed.
**Table 2  Baseline variation and changes in disability and carer burden after treatment**

<table>
<thead>
<tr>
<th>Patient disability*</th>
<th>Carer burden*</th>
</tr>
</thead>
<tbody>
<tr>
<td>BT-A</td>
<td>Placebo</td>
</tr>
<tr>
<td><strong>Baseline:</strong></td>
<td></td>
</tr>
<tr>
<td>Week –1</td>
<td>2.0 (1.4, 2.6)†</td>
</tr>
<tr>
<td>Week 0</td>
<td>2.3 (1.5, 2.6)†</td>
</tr>
<tr>
<td><strong>Post-treatment change:</strong></td>
<td></td>
</tr>
<tr>
<td>Week 0 to 2</td>
<td>–0.6 (–1.4, –0.3)</td>
</tr>
<tr>
<td>Week 0 to 6</td>
<td>–0.5 (–1.0, –0.2)</td>
</tr>
<tr>
<td>Week 0 to 12</td>
<td>–0.5 (–1.3, 0)</td>
</tr>
</tbody>
</table>

*Median (25, 75 percentiles). †Baseline disability rating significantly greater in placebo group than BT-A group. ‡Variable carer burden rating at baseline.

**Results**

Table 1 shows the clinical features of the treatment groups. The four patients with dysphasia had sufficient language ability to give informed consent and complete the assessment protocol. Data on all 20 patients randomised to receive botulinum toxin and 18 out of 20 patients randomised to receive placebo were available for analysis at the primary end point (week 6). Data were not available for two patients in the placebo group, who were unable to attend the week 6 assessment.

**Patient disability**

Baseline variation and change in patient disability rating after treatment is shown in Table 2. Less disability was reported at week 6 in the BT-A group compared with placebo. A median reduction of 0.5 seems modest in relation to the range of the disability scale (0 to 4). However, the BT-A group had a median pretreatment disability score of 2.3, with an improvement of 22% (0.5/2.3) at 6 weeks compared with the placebo group, which improved 4.7%. Moreover, the BT-A group had less scope to improve as they reported less disability than placebo. Benefits were reported at week 2 but were wearing off by week 12.

**Carer burden**

Thirty-six patients out of 40 had carers (BT-A 17 carers; placebo 19 carers). Baseline variation and change in carer burden after treatment is shown in Table 2. Physical carer burden was reduced at week 6 with BT-A compared with placebo. Reduction in carer burden was also evident at week 2 in the BT-A group and continued to at least week 12. Reduction in carer burden was particularly evident for the item “cleaning the palm”. Eight of 17 patients in the BT-A group who were dependent on carers for this activity became independent whereas all 17 patients in the placebo group who depended on their carers for this activity at baseline remained dependent.

**Spasticity**

Finger flexor spasticity at baseline was similar between groups (BT-A: median 5, IQR 5, 5; placebo: median 5, IQR 4.3, 5). Finger flexor spasticity improved with BT-A (median change –1.5, IQR –2.8, 0) compared with placebo (median change 0, IQR 0, 0; p<0.001) 6 weeks post-treatment (Table 3). Improvement with BT-A was also present at week 2 and week 12. Elbow flexor spasticity at baseline was similar between groups (BT-A: median 4, IQR 2, 5; placebo: median 3, IQR 2, 4). Significant reduction in spasticity was evident at week 2 after BT-A compared with placebo; however, no significant difference was evident at weeks 6 and 12 (Table 3). There was also no change in shoulder adductor spasticity with BT-A (median change 0, IQR –0.3, 0; p = 0.22).

**Range of arm movement**

At baseline, only 14/40 had voluntary elbow movement and 3/40 voluntary wrist movement. Active ROM was not changed with BT-A in comparison with placebo. Passive elbow extension was recorded as 0 if full extension was possible (+ve values indicating flexion deformity). There was no improvement in overall passive ROM at the elbow or shoulder between groups. However, in those patients with restriction of passive elbow extension at baseline (BT-A, 7/20; placebo, 4/20) greater improvement was seen with BT-A (median change 11 degrees; range 3–27) compared with placebo (median change 7 degrees; range 0–9) although not statistically significant. Passive

---

**Table 3  Baseline variation and changes in modified Ashworth score after treatment**

<table>
<thead>
<tr>
<th>Finger flexor spasticity*</th>
<th>Elbow flexor spasticity*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BT-A</strong></td>
<td><strong>Placebo</strong></td>
</tr>
<tr>
<td><strong>Baseline:</strong></td>
<td></td>
</tr>
<tr>
<td>Week –1</td>
<td>5 (5, 5)</td>
</tr>
<tr>
<td>Week 0</td>
<td>5 (5, 5)</td>
</tr>
<tr>
<td><strong>Post-treatment change:</strong></td>
<td></td>
</tr>
<tr>
<td>Week 0 to 2</td>
<td>–2.0 (–3.0, –0.3)</td>
</tr>
<tr>
<td>Week 0 to 6</td>
<td>–1.5 (–2.8, 0)</td>
</tr>
<tr>
<td>Week 0 to 12</td>
<td>–1.0 (–2.0, 0)</td>
</tr>
</tbody>
</table>

*Median (25, 75 percentiles).
wrist dorsiflexion improved with BT-A (median change +20 degrees; IQR 5, 31) compared with placebo (median change +3 degrees; IQR=7, 14; p=0.006). Differences of this magnitude were also seen at weeks 2 and 12 post-treatment.

**ARM PAIN**
Twenty six (65%) of the cohort reported arm pain in the week preceding intervention. All patients were included in the analysis of treatment effect. Baseline pain scores were similar between groups (BT-A: median 6.0, IQR 0, 16; placebo: median 6.0, IQR 0, 21). Arm pain was not improved at week 6 (BT-A: median change −2, IQR −10, 0; placebo: median change 0, IQR−5, 0). A significant difference in MRC grading was found between the two groups at 6 weeks. MVG was reduced with BT-A (mean change: −10.7 N (SD 13.1)) compared with placebo (mean change: +0.3 N (SD 10.1)) 6 weeks post-treatment. However the BT-A treated group did have a significantly higher MVG than the placebo group at baseline (BT-A: mean 26.7 N (SD 18.7); placebo: mean 13.3 N (SD 15.5)).

**ADVERSE EVENTS**
In the BT-A group, two patients developed self limiting arm pain within 1 week of injection and one patient reported worsening of muscle spasm. No serious BT-A related adverse events were reported. In the placebo group, one patient reported herpes labialis 7 days post-injection, one patient reported two transient ischaemic attacks 12 days postinjection, and one patient had exacerbation of cardiac failure 4 weeks after treatment.

**Discussion**
This study shows that botulinum toxin can reduce disability and carer burden in people who have long standing stroke with spasticity in a functionally useless arm. This finding is contrary to that reported by Simpson et al11 who did not identify significant effects on disability or carer burden. This may have partly reflected the muscles treated (elbow and wrist flexors only); this would not have a significant difference in MRC grading was found between the two groups at 6 weeks. MVG was reduced with BT-A (mean change: −10.7 N (SD 13.1)) compared with placebo (mean change: +0.3 N (SD 10.1)) 6 weeks post-treatment. However the BT-A treated group did have a significantly higher MVG than the placebo group at baseline (BT-A: mean 26.7 N (SD 18.7); placebo: mean 13.3 N (SD 15.5)).

No significant difference in MRC grading was found between the two groups at 6 weeks. MVG was reduced with BT-A (mean change: −10.7 N (SD 13.1)) compared with placebo (mean change: +0.3 N (SD 10.1)) 6 weeks post-treatment. However the BT-A treated group did have a significantly higher MVG than the placebo group at baseline (BT-A: mean 26.7 N (SD 18.7); placebo: mean 13.3 N (SD 15.5)).
Botulinum toxin type A, disability, and carer burden due to arm spasticity after stroke

Patients with upper limb spasticity due to stroke may experience disability attributable to spasticity but also on the prospect of relieving carer burden. Although this treatment is easy to administer and well tolerated, muscle weakness may occur and therefore the potential impact of weakness on functional activities must be assessed before intervention. Concomitant use of splints, arm mobilisation exercises, and electrical stimulation may increase the magnitude and duration of the functional effect of BT-A as well as the possibility of reducing contracture, particularly if used during the early phase of rehabilitation. These assertions need to be explored.

We are grateful to Northern and Yorkshire Regional Health Authority and Ipsen Ltd for funding this study. We thank the staff of the Community Rehabilitation Unit, St Mary’s Hospital, Leeds for their support and Mr Andy Vail, Medical Statistics Unit, University of Leeds for statistical advice.

17 Add to the examination of the peripheral nervous system. London: Medical Research Council, The Stationery Office, 1976. (Memorandum No 45.)

www.jnnp.com
Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial

Bipin B Bhakta, J Alastair Cozens, M Anne Chamberlain and John M Bamford

*J Neurol Neurosurg Psychiatry* 2000 69: 217-221
doi: 10.1136/jnnp.69.2.217

Updated information and services can be found at:
http://jnnp.bmj.com/content/69/2/217

These include:

**References**

This article cites 14 articles, 6 of which you can access for free at:
http://jnnp.bmj.com/content/69/2/217#BIBL

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Errata**

An erratum has been published regarding this article. Please see [next page](http://jnnp.bmj.com/content/69/2/217#BIBL) or:

**Topic Collections**

Articles on similar topics can be found in the following collections

- Drugs: CNS (not psychiatric) (1945)
- Neuromuscular disease (1311)
- Pain (neurology) (763)
- Stroke (1449)
- Musculoskeletal syndromes (537)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/